The effect of α-galactosylceramide (α-GalCer) on lipopolysaccharide (LPS)-induced nitric oxide (NO) production in mouse peritoneal cells was studied. α-GalCer augmented LPS-induced NO production in mouse peritoneal cells, but not in RAW 264.7 macrophage cells. α-GalCer augmented NO production, but not tumor necrosis factor (TNF)-α production in LPS-stimulated peritoneal cells. Peritoneal cells produced a significant level of interferon (IFN)-γ in response to α-GalCer and anti-IFN-γ antibody abolished the augmentation of LPS-induced NO production by α-GalCer. Moreover, anti-IFN-γ antibody prevented the enhanced expression of an inducible type of NO synthase mRNA by α-GalCer. α-GalCer did not augment LPS-induced NO production in peritoneal cells from natural killer T (NKT)-deficient mice. Therefore, it was suggested that α-GalCer might augment LPS-induced NO production in peritoneal cells through release of IFN-γ from NKT cells.
Kawano T., Cui J., Koezuka Y. et al. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells. Proc Natl Acad Sci USA1998; 95: 5690—5693.
2.
Nieda M., Nicol A., Koezuka Y. et al. Activation of human Valpha24 NKT cells by alpha-glycosylceramide in a CD1d-restricted and Valpha24 TCR-mediated manner. Hum Immunol1999; 60: 10—19.
3.
Kitamura H., Iwakabe K., Yahata T. et al. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med1999; 189: 1121—1128.
4.
Hayakawa Y., Godfrey DI, Smyth MJAlpha-galactosylceramide: potential immunomodulatory activity and future application . Curr Med Chem2004; 11: 241—252.
5.
Taniguchi M. , Harada M., Kojo S., Nakayama T., Wakao H.The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu Rev Immunol2003; 21: 483—513.
6.
Wilson MT, VanKaer L. Natural killer T cells as targets for therapeutic intervention in autoimmune diseases. Curr Pharm Des2003; 9: 201—220.
7.
Yamamura T., Miyamoto K., Illes Z., Pal E., Araki M., Miyake S.NKT cell-stimulating synthetic glycolipids as potential therapeutics for autoimmune disease. Curr Top Med Chem2004; 4: 561—567.
8.
Yokochi T., Morikawa A., Kato Y., Sugiyama T., Koide N.Apoptotic cell death in response to LPS. Prog Clin Biol Res1998; 397: 235—242.
9.
Morikawa A., Kato Y., Sugiyama T. et al. Role of nitric oxide in lipopolysaccharide-induced hepatic injury in D-galactosaminesensitized mice as an experimental endotoxic shock model . Infect Immun1999; 67: 1018—1024.
10.
Bannerman DD , Goldblum SEMechanisms of bacterial lipopolysaccharide-induced endothelial apoptosis. Am J Physiol2003; 284: L899—L914.
11.
MacMicking J., Xie QW, Nathan C.Nitric oxide and macrophage function. Annu Rev Immunol1997; 15: 323—350.
12.
Magazine HIDetection of endothelial cell derived nitric oxide: current trends and future directions. Adv Neuroimmunol1995; 5: 479—490.
13.
Rao KMMolecular mechanisms regulating iNOS expression in various cell types. J Toxicol Environ Health B2000; 3: 27—58.
14.
Sarih M., Souvannavong V., Adam A.Nitric oxide synthase induces macrophage death by apoptosis. Biochem Biophys Res Commun1993; 191: 503—508.
15.
Albina JE, Cui S., Mateo RB, Reichner JSNitric oxide-mediated apoptosis in murine peritoneal macrophages. J Immunol1993; 150: 5080—5085.
16.
Messmer UK, Ankarcrona M., Nicotera P., Brune B.p53 expression in nitric oxide-induced apoptosis. FEBS Lett1994; 355: 23—26.
17.
Green LC, Wagner DA, Glogowski J., Skipper PL, Wishnok JS, Tannenbaum SRAnalysis of nitrate, nitrite, and 15N nitrate in biological fluids. Anal Biochem1982; 126: 131—138.
18.
Koide N., Sugiyama T., Mori I. et al. Change of mouse CD5(+) B1 cells to a macrophage-like morphology induced by gamma interferon and inhibited by interleukin-4. Clin Diagn Lab Immunol2002; 9: 1169—1174.
19.
Beutler BA, Milsark IW, Cerami A.Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. J Immunol1985; 135: 3972—3977.
20.
Dieli F., Sireci G., Russo D. et al. Resistance of natural killer T cell-deficient mice to systemic Shwartzman reaction. J Exp Med2000; 192: 1645—1652.
21.
Vinay DS, Choi BK, Bae JS, Kim WY, Gebhardt BM, Kwon BSCD137-deficient mice have reduced NK/NKT cell numbers and function, are resistant to lipopolysaccharide-induced shock syndromes, and have lower IL-4 responses . J Immunol2004; 173: 4218—4229.
Emoto M., Miyamoto M., Yoshizawa I. et al. Critical role of NK cells rather than V alpha 14(+) NKT cells in lipopolysaccharide-induced lethal shock in mice. J Immunol2002; 169: 1426—1432.
24.
Wilson MT, Singh AK, VanKaer L. Immunotherapy with ligands of natural killer T cells. Trends Mol Med2002; 8: 225—231.
